Anastasia Bougea1, Christos Koros2, Maria Stamelou3, Athina Simitsi2, Nikolaos Papagiannakis2, Roubina Antonelou2, Dimitra Papadimitriou4, Marianthi Breza5, Konstantinos Tasios2, Stella Fragkiadaki2, Xenia Geronicola Trapali6, Mara Bourbouli1, Georgios Koutsis5, Sokratis G Papageorgiou2, Elisabeth Kapaki1, George P Paraskevas1, Leonidas Stefanis7. 1. 1st Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece. 2. 2nd Department of Neurology, Attikon Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece. 3. 2nd Department of Neurology, Attikon Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Neurology, Philipps University, Marburg, Germany. 4. Neurology Clinic, Henry Dunan Hospital, Athens, Greece. 5. Neurogenetics Unit, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece. 6. Nuclear Medicine Unit, Attikon Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece. 7. 2nd Department of Neurology, Attikon Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Center of Clinical Research, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece. Electronic address: lstefanis@bioacademy.gr.
Abstract
INTRODUCTION: The p.A53T point mutation in SNCA, the alpha-synuclein gene, has been linked to a rare dominant form of Parkinson's disease (PD). METHODS: Here, we describe two apparently unrelated cases of p.A53T (G209A) SNCA mutation carriers with an atypical initial manifestation and disease course. Moreover, cerebrospinal fluid (CSF) levels of tau, p-tau and amyloid Aβ42 were measured in these patients and in an additional cohort of 5 symptomatic and 2 asymptomatic p.A53T carriers without an initial manifestation of dementia. RESULTS: Both patients exhibited an early onset frontal-dysexecutive dysfunction with apathy and emotional blunting resembling frontotemporal dementia (FTD). Motor symptoms typical of Parkinson's disease appeared only later in the disease course and were less prominent than cognitive ones, which included language impairment. Autonomic dysfunction and myoclonus also emerged in a more advanced disease stage. In both patients, Brain Magnetic Resonance Imaging showed fronto-temporo-parietal atrophy, and CSF analysis showed elevated tau protein levels. In contrast, tau protein levels were normal in a cohort of 7 other p.A53T mutation carriers (5 symptomatic/2 asymptomatic). A screen of Greek patients presenting with frontotemporal dementia failed to identify any additional subjects with the p.A53T SNCA mutation. CONCLUSION: Although cognitive decline has been recognized as a feature of the full-blown clinical picture of p.A53T related parkinsonism, a predominant frontotemporal dementia-like phenotype at presentation has not been previously described. This may represent a subtype of this disorder, with distinctive clinical, imaging and CSF biochemical characteristics, in which additional genetic or epigenetic factors may play a role.
INTRODUCTION: The p.A53T point mutation in SNCA, the alpha-synuclein gene, has been linked to a rare dominant form of Parkinson's disease (PD). METHODS: Here, we describe two apparently unrelated cases of p.A53T (G209A) SNCA mutation carriers with an atypical initial manifestation and disease course. Moreover, cerebrospinal fluid (CSF) levels of tau, p-tau and amyloid Aβ42 were measured in these patients and in an additional cohort of 5 symptomatic and 2 asymptomatic p.A53T carriers without an initial manifestation of dementia. RESULTS: Both patients exhibited an early onset frontal-dysexecutive dysfunction with apathy and emotional blunting resembling frontotemporal dementia (FTD). Motor symptoms typical of Parkinson's disease appeared only later in the disease course and were less prominent than cognitive ones, which included language impairment. Autonomic dysfunction and myoclonus also emerged in a more advanced disease stage. In both patients, Brain Magnetic Resonance Imaging showed fronto-temporo-parietal atrophy, and CSF analysis showed elevated tau protein levels. In contrast, tau protein levels were normal in a cohort of 7 other p.A53T mutation carriers (5 symptomatic/2 asymptomatic). A screen of Greek patients presenting with frontotemporal dementia failed to identify any additional subjects with the p.A53TSNCA mutation. CONCLUSION: Although cognitive decline has been recognized as a feature of the full-blown clinical picture of p.A53T related parkinsonism, a predominant frontotemporal dementia-like phenotype at presentation has not been previously described. This may represent a subtype of this disorder, with distinctive clinical, imaging and CSF biochemical characteristics, in which additional genetic or epigenetic factors may play a role.
Authors: Peter J Teravskis; Ana Covelo; Eric C Miller; Balvindar Singh; Héctor A Martell-Martínez; Michael A Benneyworth; Christopher Gallardo; Breeta R Oxnard; Alfonso Araque; Michael K Lee; Dezhi Liao Journal: J Neurosci Date: 2018-09-24 Impact factor: 6.167
Authors: Velmarini Vasquez; Joy Mitra; Haibo Wang; Pavana M Hegde; K S Rao; Muralidhar L Hegde Journal: Prog Neurobiol Date: 2019-12-18 Impact factor: 11.685
Authors: Balvindar Singh; Ana Covelo; Héctor Martell-Martínez; Carmen Nanclares; Mathew A Sherman; Emmanuel Okematti; Joyce Meints; Peter J Teravskis; Christopher Gallardo; Alena V Savonenko; Michael A Benneyworth; Sylvain E Lesné; Dezhi Liao; Alfonso Araque; Michael K Lee Journal: Acta Neuropathol Date: 2019-06-06 Impact factor: 17.088
Authors: Rita Guerreiro; Elizabeth Gibbons; Miguel Tábuas-Pereira; Celia Kun-Rodrigues; Gustavo C Santo; Jose Bras Journal: Neurobiol Dis Date: 2020-05-19 Impact factor: 5.996